预约演示
Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster
临床2期并购IPO临床3期临床失败
A phase 2b trial in ulcerative colitis is scheduled to report data in 2025.
Eli Lilly has agreedulcerative colitisr $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio.
ElipLilly pipeline is led byMorphic57. The oral small molecule inhibits α4β7, an integrin expressed on some white bloodTakeda. Takeda showeinflammatory bowel diseasean control inEntyviol inflammation and improve outcomes in ulcerative colitis and Crohn’s disease. The data turned Entyvio into a big product for Takeda, but its injectable delivery format left the door open for more convenient oral challengers.
Morphicas come crashing throuMORF-057oor. Buying Morphic will give Lillyα4β7ership of an oral challenger to Entyvio that is in phase 2 development in ulcerintegrinlitis and Crointestinal inflammation-057 into phase 2 in 2022ulcerative colitisthan Crohn’s disease Gilead Sciences' Entyvioral α4β7 candidate. Lilly previously acquired a preclinical oral α4β7 program in its $2.4 billion takeover of Dice Therapeutics.
Lilly Therapeutics, which recently bought a phase 2-ready oral α4β7Lillypect from Eisai’s GI subsidiary EA PEntyviois the other front-runner in the raulcerative colitisyvio.Crohn’srops to date haMORF-057raised and dashed hopes that oral molecules are a threat to Gilead Sciencesuster.α4β7Lillyα4β7Dice Therapeutics
Ensho Therapeuticseutics scrapped its first oral α4β7 antagonisα4β7ptide after seeEisaihase 2b results iEA Pharmahe biotech regrouped behind a second-generation prosEntyviolaimed to be delighted by the phase 2 data and then promptly dropped the asset rather than start a planned pivotal trial.
Protagonist Therapeuticstially, reporting a cliniα4β7 antagonist peptide suggested MORF-057 may match the efficacy of Entyvio and sending investors into a buying frenzy. But the candidate's failure to trigger the expected level of endoscopic improvement sent Morphic’s stock back down when the biotech shared a fuller look at the data months later.
Morphica share, Lilly’s takeover values Morphic at around the price the stock commaMORF-057the wake of the release of Entyvioe phase 2a data in April 2023. Morphic’s share price never recovered from the publication of more data, allowing Lilly to offer an 87%Morphicm to the 30-day volume-weighted average trading price of Morphic's share price and still keep the buyout price down to $3.2 billion.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。